About us | Advertise with us | Contact us
Posted: 9 June 2021 | Hannah Balfour (European Pharmaceutical Review) | No comments yet
The continuous-flow microfluidic device allows scientists to assess crystalline API growth rates, shapes and structures to more quickly identify the best conditions for drug manufacturing.
A newly developed continuous-flow microfluidic device may help pharmaceutical companies more effectively study drug compounds and their crystalline shapes and structures, both key components for drug stability.
The device developed by researchers at the University of Illinois Chicago (UIC), US, consists of a series of wells in which a drug solution – an active pharmaceutical ingredient (API) dissolved in a solvent, such as water – can be mixed with an anti-solvent in a highly controlled manner. When mixed together, the two solutions allow for the API crystals to form a nucleus and grow. The device allows scientists to alter the rates and ratios at which the solution is mixed with the anti-solvent, creating multiple conditions for crystal growth. As the crystals grow in different conditions, data on their growth rates, shapes and structures is gathered and imported into a data network.
According to its developers, this data cane then be used to more quickly identify the best conditions for manufacturing the most stable crystalline form with a desirable crystal morphology – a crystal with a plate-like shape instead of a crystal with a rod-like shape – of an API and scale up the crystallisation of stable forms.
The UIC researchers led by Meenesh Singh, in collaboration with the Enabling Technologies Consortium, have validated the device using L-histidine, the API in medications being developed to treat conditions like rheumatoid arthritis, allergic diseases and ulcers. This research was published in Lab on a Chip, a journal of the Royal Society of Chemistry.
An illustration of the continuous-flow microfluidic device for rapid screening of crystals of active pharmaceutical ingredients. As crystals grow, automated data acquisition and parallel processing allow for high-throughput screening, which can help to engineer better medicines [Credit: Meenesh Singh/UIC].
“The pharmaceutical industry needs a robust screening system that can accurately determine API polymorphs and crystallisation kinetics in a shorter time frame. But most parallel and combinatorial screening systems cannot control the synthesis conditions actively, thereby leading to inaccurate results,” said Singh, UIC assistant professor of chemical engineering at the College of Engineering. “In this paper, we show a blueprint of such a microfluidic device that has parallel-connected micromixers to trap and grow crystals under multiple conditions simultaneously.”
In their study, the researchers found that the device was able to screen polymorphs, morphology and growth rates of L-histidine in eight different conditions. The conditions included variations in molar concentration, percentage of ethanol by volume and supersaturation – important variables which influence the crystal growth rate. The overall screening time for L-histidine using the multi-well microfluidic device was about 30 minutes, which the team said is at least eight times shorter than a sequential screening process.
The researchers also compared the screening results with a conventional device. They found that the conventional device significantly overestimated the fraction of stable form and showed high uncertainty in measured growth rates.
“The multi-well microfluidic device paves the way for next-generation microfluidic devices that are amenable to automation for high-throughput screening of crystalline materials,” Singh said. He concluded that better screening devices could improve API process development efficiency and enable timely and robust drug manufacturing, which could ultimately lead to safer drugs that cost less money.
Thermogelling nanoemulsion enhances drug loading of hydrophobic APIs…
Active Pharmaceutical Ingredient (API), Analytical techniques, Drug Development, Drug Manufacturing, Drug Safety, Formulation, Microfluidics, QA/QC, Research & Development (R&D), Screening
Enabling Technologies Consortium, University of Illinois Chicago (UIC)
By Hannah Balfour (European Pharmaceutical Review)
Active Pharmaceutical Ingredient (API), Analytical techniques, Drug Development, Drug Manufacturing, Drug Safety, Formulation, Microfluidics, QA/QC, Research & Development (R&D), Screening
Enabling Technologies Consortium, University of Illinois Chicago (UIC)
All subscriptions include online membership, giving you access to the journal and exclusive content.
By Hannah Balfour (European Pharmaceutical Review)
By Hannah Balfour (European Pharmaceutical Review)
By Mandy Parrett (European Pharmaceutical Review)
Your email address will not be published. Required fields are marked *
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Write for us | Advertise with us
European Pharmaceutical Review is published by: Russell Publishing Ltd. Court Lodge Hogtrough Hill Brasted, Kent, TN16 1NU United Kingdom
© Russell Publishing Limited, 2010-2022. All rights reserved.
Website development by e-Motive Media Limited.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
CookieDescriptioncookielawinfo-checkbox-advertising-targetingThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".cookielawinfo-checkbox-analyticsThis cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".cookielawinfo-checkbox-necessaryThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".cookielawinfo-checkbox-performanceThis cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".PHPSESSIDThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.viewed_cookie_policyThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.zmember_loggedThis session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.